Chengdu StarRay Therapeutics

StarRay Therapeutics is a biopharmaceutical company based in Chengdu, China, specializing in the discovery and development of innovative small molecule drugs that target RNA and RNA-binding proteins. The company leverages a proprietary platform to address undruggable targets in oncology, immunology, and metabolic diseases. Founded by industry veterans with experience in global pharma, StarRay has secured significant venture capital from prominent investors like Lilly Asia Ventures and GL Ventures. Their pipeline is currently in the pre-clinical and IND-enabling stages, focusing on high-value therapeutic targets with high unmet medical needs. The company aims to redefine the scope of small molecule therapeutics through its focus on RNA modulation.